SCHEMBL13097549

SCHEMBL13097549

Cc1c(COC(=O)N2CCN(C(=O)CCc3ccccc3)CC2)[nH]c2ccccc2c1=O

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.60
MAPT P10636 5/20 0.52
HSD17B10 Q99714 3/20 0.52
USP2 O75604 1/20 0.48
ALDH1A1 P00352 5/20 0.48
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 6/20 0.44
NPC1 O15118 4/20 0.44
GAA P10253 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
RAB9A P51151 3/20 0.44
POLB P06746 1/20 0.44
ME2 P23368 1/20 0.43
ME1 P48163 1/20 0.43
ME3 Q16798 1/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
FKBP1A P62942 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13097792 0.81 KMT2A (0.51) MAPTHSD17B10ALDH1A1LMNASMN1; SMN2
SCHEMBL13097552 0.81 ALDH1A1 (0.57) L3MBTL1MAPTHSD17B10USP2ALDH1A1
SCHEMBL13097836 0.81 SMN1; SMN2 (0.51) L3MBTL1MAPTHSD17B10USP2ALDH1A1
SCHEMBL13097801 0.80 SMN1; SMN2 (0.50) L3MBTL1MAPTHSD17B10USP2ALDH1A1
SCHEMBL13097730 0.79 ALDH1A1 (0.53) MAPTHSD17B10USP2ALDH1A1LMNA
SCHEMBL13548728 0.77 L3MBTL1 (0.79) L3MBTL1MAPTALDH1A1LMNASMN1; SMN2
SCHEMBL13097537 0.76 ALDH1A1 (0.58) MAPTHSD17B10USP2ALDH1A1LMNA
SCHEMBL13097800 0.74 CYP2D6 (0.51) MAPTHSD17B10USP2ALDH1A1LMNA
SCHEMBL13097929 0.73 CAPN1 (0.46) MAPTALDH1A1TDP1POLBKMT2A
SCHEMBL13097743 0.73 ALDH1A1 (0.53) MAPTHSD17B10ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367702-B2 Quinolone derivative ASTELLAS PHARMA INC. (JP) 2013-02-05 US disclosed
US-8367702-B2 Quinolone derivative ASTELLAS PHARMA INC. (JP) 2013-02-05 US disclosed
US-20100256113-A1 QUINOLONE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2010-10-07 US disclosed
US-20100256113-A1 QUINOLONE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2010-10-07 US disclosed
EP-2194044-A1 QUINOLONE DERIVATIVE Astellas Pharma Inc. (JP) 2010-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256113-A1 QUINOLONE DERIVATIVE NQO1, NQO2, NADK L3MBTL1 2056/4885MAPT 4661/4885HSD17B10 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.